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Abstract
Summary We evaluated the influence of long-term HIV
infection and its treatment on distal tibia and radius micro-
structure. Premenopausal eumenorrheic HIV-positive wom-
en displayed trabecular and cortical microstructure
alterations, which could contribute to increased bone fragil-
ity in those patients.
Introduction Bone fragility is an emerging issue in HIV-
infected patients. Dual-energy X-ray absorptiometry (DXA)
quantified areal bone mineral density (BMD) predicts fracture
risk, but a significant proportion of fracture risk results from
microstructural alterations.
Methods We studied the influence of long-term HIV infec-
tion on bone microstructure as evaluated by high-resolution
peripheral quantitative computed tomography (HR-pQCT)
in 22 HIV-positive (+ve) premenopausal eumenorrheic
women and 44 age- and body mass index (BMI)-matched
HIV-negative (−ve) controls. All subjects completed ques-
tionnaires regarding calcium/protein intakes and physical
activity, and underwent DXA and HR-pQCT examinations
for BMD and peripheral skeleton microstructure, respective-
ly. A risk factor analysis of tibia trabecular density using
linear mixed models was conducted.
Results In HIV+ve women on successful antiretroviral ther-
apy (undetectable HIV-RNA, median CD4 cell count, 626),
infection duration was 16.5±3.5 (mean ± SD)years; median
BMI was 22 (IQR, 21–26)kg/m2. More HIV+ve women
were smokers (82 versus 50 %, p00.013). Compared to
controls, HIV+ve women had lower lumbar spine (spine
T-score −0.70 vs −0.03, p00.014), but similar proximal
femur BMD. At distal tibia, HIV+ve women had a 14.1 %
lower trabecular density and a 13.2 % reduction in trabecu-
lar number compared to HIV−ve women (p00.013 and
0.029, respectively). HR-pQCT differences in distal radius
were significant for cortical density (−3.0 %; p00.029).
Conclusions Compared with HIV−ve subjects, premeno-
pausal HIV+ve treated women had trabecular and cortical
bone alterations. Adjusted analysis revealed that HIV status
was the only determinant of between group tibia trabecular
density differences. The latter could contribute to increased
bone fragility in HIV+ve patients.
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Introduction
Osteoporosis and low bone mineral density (BMD), as well
as increased fracture risk, are major complications that are
still incompletely understood in individuals with HIV infec-
tion treated by antiretroviral therapy [1–4]. Numerous stud-
ies have reported increased prevalence of low BMD in HIV-
positive (+ve) patients compared to HIV-uninfected persons.
The proportion of HIV+ve individuals with osteopenia or
osteoporosis in cross-sectional studies ranged from 40 up to
88 % [5]. An important contributor of bone strength is areal
BMD (aBMD), expressed in grams per square centimeter
and measured at the lumbar or proximal femoral sites using
dual-energy X-ray absorptiometry (DXA) [6]. A decrease of
one standard deviation (SD) in aBMD doubles the risk of
fractures with a continuous risk gradient. Osteopenia and
osteoporosis diagnosis are based on an operational defini-
tion relying on bone mineral density thresholds [7, 8].
In addition to aBMD, bone microstructure is a key determi-
nant of bone fragility as bone loss is accompanied by a thinning
of the spans and by perforations that compromise the overall
strength of the supporting tissue [9, 10]. Measurement techni-
ques allow one to analyze the trabeculae in terms of number,
thickness, and architectural organization, but are often inva-
sive. High-resolution peripheral quantitative computed tomog-
raphy (HR-pQCT) is a novel non-invasive tool that allows the
analysis of such variables. This instrument is capable of eval-
uating bone volume, the number, thickness and separation of
trabeculae, connectivity, and cortical thickness in vivo, at high
resolution (82 μm). Trabeculae in humans are 100–150 μm
thick. For the same value of aBMD, subjects with fracture have
an altered microstructure, thus emphasizing the importance of
this approach to assess bone fragility pathogenesis and fracture
risk [11–13]. HR-pQCT has been used in different populations,
but not in a particularly fragile population such as individuals
living with HIVand treated with antiretroviral agents.
In this study, we aimed to detect differences in areal and
volumetric BMD and in cortical and trabecular bone micro-
structure in a young premenopausal female population with
and without HIV infection by HR-pQCT. Our hypothesis was
that quantitative bone measurements (DXA) alone do not
seem to fully appreciate the increased fracture risk in
HIV+ve treated patients. This may have the potential to detect
bone disorders at an earlier stage before any mineral mass
decrease secondary to sex hormone deprivation ofmenopause.
Subjects and methods
Study design and population
We conducted a 2:1 case–control study in HIV+ve (n022) and
HIV negative (−ve) age- and bodymass index (BMI)-matched
premenopausal women (n044). Cases were HIV+ve Cauca-
sian premenopausal women followed up at the HIV Unit
of Geneva University Hospital, Geneva, Switzerland,
with a minimum duration of HIV infection of 5 years.
Patients had to be on effective antiretroviral therapy (HIV-
RNA <40 copies/mL), with or without oral contraception
medication. Exclusion criteria were pregnant women, women
with amenorrhea, or a history of low energy bone fracture.
Control subjects were selected from a cohort of premenopaus-
al women recruited within the Geneva area [14]. Calcium and
protein intakes, as well as physical activity, were assessed by
frequency questionnaires as previously described [14]. The
same questionnaires were used for both cases and controls and
administered by the same investigator (a certified dietician).
All subjects provided written informed consent before partic-
ipation. The protocol was approved by the ethics committee of
the Geneva University Hospitals.
DXA and HR-pQCT measurements
Bone variables were measured by the same technicians
during the whole study period. aBMD (grams per square
centimeter) was measured by DXA at the level of the lumbar
spine, femoral neck, and total hip by bone densitometers
(QDR-4500 and Discovery A; Hologic, Inc, Bedford, MA,
USA) with a coefficient of variation (CV) of repeated meas-
urements varying between 1.0 and 1.5 %, as previously
reported [15, 16]. The aBMD phantom CV for the DXA
case measurement period was 0.34 %.
Volumetric BMD (vBMD) and microstructure were de-
termined at the distal tibia and distal radius by HR-pQCT
using an XtremeCT instrument (Scanco Medical, Brütti-
sellen, Switzerland) as previously described [11, 14, 17].
The following variables were measured: total, cortical, and
trabecular volumetric densities expressed in milligram hy-
droxyapatite (HA) per cubic centimeter; trabecular number,
thickness (micrometer), and separation (micrometer); mean
cortical thickness (millimeter), cortical area (square milli-
meter) and porosity (percentage); pores mean and variability
size (millimeter); and polar moment of inertia (millimeter to
the fourth power). The in vivo short-term reproducibility of
HR-pQCT at the distal tibia and distal radius varied from 0.7
to 1.0 % and 0.6 to 1.0 % for bone density, and from 3.0 to
4.9 % and 2.8 to 4.9 % for trabecular microstructure, re-
spectively [14, 17]. The vBMD phantom CV was 0.39 % for
the HR-pQCT case measurement period.
HR-pQCT images were filtered (Laplace-Hamming fil-
ter; Scanco Medical) and binarized according to the manu-
facturer’s standard instructions. The cortical and trabecular
regions were segmented using an automated segmentation
method implemented in Image Processing Language (IPL
V5.07; Scanco Medical). This method uses two threshold
values and a series of morphologic operations (e.g., dilation
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and erosion operations) to extract the endosteal and perios-
teal surfaces of the cortex, which is based on the assumption
that the trabecular region is enclosed by a cortical shell. The
manufacturer’s standard instructions for the use of a Gauss-
ian filter and threshold (filter threshold) were applied also
for comparison [18]. Owing to hardware constraints, the
Laplace–Hamming filter could not be used on the 19-mm
μCT images. Therefore, they were filtered using a Gaussian
filter (s¼ 1.2, support ¼2) and binarized using a global
threshold of 18.4 % of the maximum value, which is a
standard analysis method for μCT images. The cortical
and trabecular regions were segmented by semi-automatic,
hand-drawn contours around both the endosteal and perios-
teal surfaces. Cortical porosity was calculated as the number
of void voxels in each binary cortex image divided by the
total number of voxels in the cortex using IPL. The number
of individual pores was counted using component labeling
(IPL, Scanco Medical), and the mean pore volume was
calculated as the total volume of porosity divided by the
pore number [19].
Biochemical determinations
Serum biochemical values were available only for HIV+ve
subjects and were determined by the central chemistry lab-
oratory at the Geneva University Hospital (quality assur-
ance # STS 553). HIV-related parameters, such as CD4 cell
count, HIV-RNA, and CD4 cell count nadir, were extracted
from the Swiss HIV Cohort Study at the closest time point
to the measurement visit time (3 months’ window). Blood
samples were collected between 7 and 10 am after overnight
fast for determination of serum levels of creatinine, total
alkaline phosphatase (ALP), albumin, calcium, phosphate,
bone-specific ALP (bone ALP), 25-hydroxvitamin D, para-
thyroid hormone (PTH), type 1 collagen amino-terminal
telopeptide (P1NP), and CTX (CrossLaps). 25-
hydroxyvitamin D3 and PTH were quantified by electro-
chemiluminescence immunoassays on a Cobas e601 analyz-
er (Roche, Basel, Switzerland) using Monoclonal Elecsys
25-OH Vitamin D3 (Roche) and Elecsys intact PTH
reagents (Roche). Bone ALP was quantified using Acces
Ostase immunoenzymatic assay (Beckman Coulter, Fuller-
ton, CA, USA) on a Unicel DxI800 analyzer (Beckman
Coulter). The lower limits of detection for these three assays
were 10 nmol/L (25-HO-D3), 0.13 pmol/L (PTH), and
0.1 μg/L (bone ALP), respectively.
Statistics
At the time of study conception, we found no published data
on distal radius or tibia microstructure (HR-pQCT) for HIV
patients. Therefore, the power calculation of this study was
computed using literature data on osteopenia in HIV+ve and
HIV−ve patients [1, 20, 21]. Cases and controls were
matched 1:2 by age (±3 years) and BMI (±0.5 kg/m2). By
including 22 HIV+ve and 44 HIV−ve premenopausal wom-
en, we estimated that we would be able to detect a propor-
tion difference of 35 % for patients with osteopenia between
the two groups, i.e., 50 % in the HIV+ve group versus 15 %
in the HIV−ve group to achieve a power level of 80 % with
an alpha threshold of 5 %.
Anthropometric and osteodensitometric variables, demo-
graphic and clinical characteristics are given as the median±
interquartile range (IQR) by HIV status at baseline (Table 1).
Differences between the two groups in bone microstructure
variables, lumbar spine, femoral neck and total hip BMD, and
Fracture Risk Assessment (FRAX) scores [22, 23] were
assessed by univariate conditional logistic regression with an
alpha threshold of 5 %. Risk factor analysis (univariate and
multivariate) of distal tibia trabecular and distal radius cortical
densities in the whole study population (n066) was first
performed using a linear mixed models grouped by pair with
an alpha threshold of 5 %. Linear mixed models did not
provide additional information as compared to linear regres-
sion (likelihood ratio test p values were not statistically sig-
nificant). HIV status, BMI (kilograms per square meter), age
(year), age at first menstrual period (year), prevalent fracture
(yes/no), prevalent upper limb fracture (yes/no), tobacco use
pack-year unit (PYU) (0–17 PYU versus 18+ PYU), alcohol
consumption (<2 units once weekly versus ≥2), logarithm
calcium intake (milligrams per day), protein intake (grams
per kilogram body weight per day), physical activity (kilo-
calories per day), and vitamin D supplementation (yes/no)
were included in an univariate linear regression model. All
variables with p<0.200 in the univariate model were entered in
a multivariate linear regression model adjusted for age and
BMI to comply with our baseline age- and BMI-matched
design, for tobacco use PYU and vitamin D supplementation
(yes/no). We assessed the effect of current or past use of
tenofovir and boosted protease inhibitor (bPI) on tibia trabec-
ular density and radius cortical density using univariate linear
regression. Statistical analysis was performed using STATA
software, version 12.0 (StataCorp, College Station, TX, USA).
Results
Comparison of characteristics between HIV+ve women
and controls
Twenty-three patients were screened, 22 included in the
study (Fig. 1). Baseline characteristics of the 22 cases
and 44 controls showed a nonsignificant trend for lower
BMI values in HIV+ve women (Table 1). The proportion
of active or past smokers was higher in the HIV+ve
group compared with the controls (82 versus 50 %,
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respectively; p00.013). Calcium intake was similar,
whereas protein intake, corrected for body weight and
expressed as grams per kilogram body weight×day, was
slightly, although not significantly, higher in the HIV+ve
group (Table 1). The level of physical activity was
13.1 % lower in the HIV+ve group.
Regarding HIV characteristics, the median duration of
infection was 16.5 (IQR,13.5–19.2) years and only included
HIV+ve women on successful antiretroviral treatment
according to study design definitions [undetectable HIV-
RNA; median CD4 cell count, 626 (IQR, 440–831), median
BMI, 21.6 (range, 20.7–25.9)kg/m2]. Current antiretroviral
therapy included eight patients (36 %) on boosted protease
Inhibitor (bPI) based therapy and ten on non-nucleoside
reverse transcriptase inhibitors (NNRTI)-based regimen
(45 %); ten patients had a backbone regimen including
tenofovir (45 %). 25-Hydroxyvitamin D3 was inferior to
target recommendations (>75 nmol/l) in 12 (57 %) subjects
(Table 2).
Comparison of bone variable measurements
between HIV+ve women and controls
DXA and HR-pQCT values in both groups are presented in
Table 3. Figure 2 represents the percent difference (HIV+ve
group versus HIV−ve controls) in distal radius and distal
Fig. 1 Study flow chart for the
recruitment of HIV+ve women
Table 1 Baseline characteristics
IQR interquartile range, BMI
body mass index, BW body
weight
*p<0.05
Premenopausal women p_value
HIV+ve HIV−ve
N022 N044
Median (IQR) Median (IQR)
Sociodemographic characteristics
Age (year) 44.3 (38.9; 46.4) 44.4 (41.3; 46.1) 0.131
BMI (kg/m2) 21.6 (20.7; 25.9) 22.0 (20.9; 24.8) 0.077
Age at first menstrual period (year) 13.0 (12.0; 14.0) 12.8 (11.7; 14.0) 0.216
Oral contraception [n (%)] 22 (100) 42 (96) 0.310
Vitamin D supplementation [n (%)] 9 (41) 2 (5) <0.0001*
Tobacco consumption
Current or ex-smoker [n (%)] 18 (82) 22 (50) 0.013
Pack-years unit 18 (5; 20) 0 (0; 15) 0.146
Alcohol consumption
Never [n (%)] 4 (18) 10 (23) 0.907
1–2 Unit weekly [n (%)] 12 (55) 21 (48)
2 or Unit weekly [n (%)] 6 (27) 13 (29)
Fractures
Prevalent fracture [n (%)] 8 (36) 23 (52) 0.656
Prevalent upper limb fracture [n (%)] 2 (9) 9 (20) 0.277
Nutrition and physical activity questionnaire:
Calcium intake (mg/day) 896.8 (582.9; 1055.0) 792.1 (556.8; 1048.8) 0.830
Protein intake (g/kg BW×day) 0.87 (0.66; 1.03) 0.75 (0.59; 0.87) 0.257
Physical activity (kcal/day) 266.5 (129.7; 358.6) 306.8 (187.0; 418.7) 0.215
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tibia microstructure median pairs. In HIV+ve women, distal
tibia trabecular density and number were lower (−14.1
and −13.2 %, respectively) and trabecular separation larger
(+15.7 %; p00.013, 0.029, and 0.037, respectively)
compared to controls (Fig. 2). HIV+ve women had also
a lower lumbar spine BMD (−6.9 %, p00.014), but
similar femoral neck and total hip BMD. Trabecular
density, number, and separation were not different between
groups at the radial site. However, a trend towards a lower
trabecular density and number in HIV+ve women (p00.06
for both values) was observed and a −3.0 % lower
cortical density (p00.029) at the radial site (Fig. 2).
No differences in cortical porosity were observed between
the two groups. The FRAX score (calibrated for Swiss
conditions), computed using a BMD-included algorithm,
showed a higher probability of hip fracture in HIV+ve women
compared to controls.
Effect of specific antiretroviral drug use
Assessment of the relationship between specific antiretrovi-
ral drugs and tibia trabecular or radius cortical density did
not show any significant effect of current/past use of teno-
fovir or bPI (data not shown).
Adjusted multivariate analysis
Risk factor analysis of distal tibia trabecular and distal radius
cortical densities in the whole study population is presented in
Table 4. HIV status was the only risk factor associated with a
reduction of tibia trabecular density and of radius cortical
density after adjustment for age, BMI, and smoking status.
The lower 28.2 mgHA/cm3 tibia trabecular density (p00.009)
in HIV+ve premenopausal women compared to HIV−ve
women corresponds to a difference of 41.2 %. The lower
Table 2 Biochemical parame-
ters and characteristics of HIV
+ve subjects
PTH parathyroid hormone,
P1NP type 1 collagen amino-
terminal telopeptide, HAART
highly active antiretroviral ther-
apy, PI protease inhibitor, bPI
boosted protease inhibitor
NNRTI non-nucleoside reverse
transcriptase inhibitors, TDF
tenofovir HBV hepatitis B, HBC
hepatitis C
HIV+ve premenopausal women (N022)
Median (IQR)
Serum parameters
Adjusted calcium (mmol/l)
[ref., 2.20–2.52 mmol/l] 2.33 (2.30; 2.36)
Albumin (g/)
[ref., 35–48 g] 37 (34; 38)
Creatinine (μmol/l)
[ref., 35–88 μmol/l] 66 (61;71)
25 OH vit. D3 nmol/l <25 [n (%)] 2 (10)
25 OH vit. D3 <50 [n (%)] 6 (29)
25 OH vit. D3 <75 [n (%)] 12 (57)
Bone-specific alkaline phosphatase (μmol/l)
[ref., 2.9–14.5 μmol/l] 12.3 (8.9; 15.5)
PTH (pmol/l)
[ref., 1.1–6.8 pmol/l] 4.4 (4.0; 5.9)
P1NP [ref., 15–59 μg/l] 43.6 (35.9; 61.9)
CTX crosslaps [ref., 162–436 ng/l] 396.5 (217.0; 556.0)
HIV characteristics:
HIV time since diagnosis (year) 16.5 (13.5; 19.2)
HIV C Stade [n (%)] 5 (23)
HAART time (year) 11.4 (8.9; 13.5)
HAART [n (%)] 22 (100)
Current PI [n (%)] 9 (41)
Current boosted PI [n (%)] 8 (36)
Current NNRTI [n (%)] 10 (45)
Current TDF [n (%)] 10 (45)
Others combination [n (%)] 3 (14)
CD4 nadir 241 (138; 322)
CD4 cell count 626 (440; 831)
Co- infections status:
HBV [n (%)] 1 (5)
HCV [n (%)] 4 (18)
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Table 3 Distal tibia and distal radius microstructure (HR-pQCT), lumbar spine and proximal femur BMD (DXA), and FRAX scores in HIV+ve
group and in HIV−ve controls
Premenopausal women
HIV+ve, n022 HIV−ve, n044
Median (IQR) Median (IQR) p valuea
HR-pQCT tibia:
Total density (mg HA/cm3) 282.7 (220.6; 314.1) 298.9 (258.1; 336.4) 0.161
Trabecular density (mg HA/cm3) 135.0 (112.6; 156.7) 157.1 (144.6; 179.6) 0.013a
Trabecular thickness (μm) 71 (63; 77) 70 (65; 82) 0.196
Trabecular number (mm−1) 1.58 (1.35; 1.76) 1.82 (1.64; 2.00) 0.029a
Trabecular separation (μm) 554 (495; 676) 479 (422; 531) 0.037a
Cortical density (mg HA/cm3) 917.8 (877.0; 931.6) 943.7 (915.5; 965.1) 0.071
Cortical thickness (mm) 1.14 (1.05; 1.30) 1.15 (0.99; 1.26) 0.776
Cortical area (mm2) 117.6 (103.4; 122.0) 117.8 (102.5; 127.0) 0.764
Cortical porosity (%) 3.43 (2.17; 3.79) 3.54 (2.57; 4.58) 0.631
Pores mean size (μm) 0.18 (0.17; 0.19) 0.18 (0.17; 0.20) 0.359
Pores variability size (μm) 0.08 (0.07; 0.09) 0.08 (0.07; 0.09) 0.482
Polar moment of inertia (1/mm4) 20625.69 (16662.97; 21291.98) 20014.52 (17435.15; 22574.24) 0.591
HR-pQCT radius:
Total density (mg HA/cm3) 319.00 (262.20; 381.90) 343.05 (309.85; 382.05) 0.228
Trabecular density (mg HA/cm3) 130.10 (108.90; 168.40) 158.05 (138.95; 179.40) 0.062
Trabecular thickness (μm) 63 (55; 69) 66 (61; 71) 0.147
Trabecular number (mm−1) 1.76 (1.41; 2.11) 1.94 (1.81; 2.13) 0.068
Trabecular separation (μm) 513 (402; 642) 443 (398; 484) 0.089
Cortical density (mg HA/cm3) 922.50 (882.90; 948.90) 951.30 (928.00; 977.90) 0.029a
Cortical thickness (mm) 0.80 (0.73; 0.98) 0.82 (0.75; 0.94) 0.961
Cortical area (mm2) 53.40 (49.00; 64.20) 55.55 (52.35; 62.35) 0.717
Cortical porosity (%) 1.13 (0.76; 1.39) 1.00 (0.78; 1.28) 0.123
Pores mean size (μm) 0.15 (0.14; 0.16) 0.15 (0.14; 0.16) 0.916
Pores variability size (μm) 0.06 (0.05; 0.07) 0.06 (0.05; 0.06) 0.861
Polar moment of inertia (1/mm4) 3853.42 (3473.34; 4464.10) 4034.60 (3650.07; 4956.19) 0.204
DXA scan:
Lumbar spine BMD (g/cm2) 1.000 (0.820; 1.077) 1.074 (1.010; 1.170) 0.014a
Femoral neck BMD (g/cm2) 0.776 (0.624; 0.898) 0.813 (0.729;0.879) 0.320
Total hip BMD (g/cm2) 0.899 (0.761; 1.021) 0.940 (0.834; 0.976) 0.652
T-scores:
Lumbar spine T-score −0.70 (−2.33; −0.00) −0.03 (−0.61; 0.85) 0.014a
Total hip T-score −0.35 (−1.48; 0.65) −0.02 (−0.88; 0.28) 0.652
Femoral neck T-score −0.66 (−2.03; 0.44) −0.33 (−1.09; 0.27) 0.320
Osteopenia
[T-score ≤1 and T-score ≥2.5] (%) 7 (32) 10 (23) 0.241
Osteoporosis [T_score <−2.5] (%) 1 (5) 0 (0)
FRAX fracture probabilityb:
% Major osteoporotic fractures 4.9 (2.6; 5.9) 4.4 (2.8; 5.4) 0.326
% Hip fracture 0.4 (0.0; 2.1) 0.1 (0.1; 0.4) 0.029a
IQR interquartile range, BMD bone mineral density, FRAX refers to the WHO released FRAX tool to assess fracture risk based on a clinical and
BMD-based score
a p_values were obtained from univariate conditional logistic model
b FRAX score 10-year fracture risk probability was computed with femoral neck BMD values
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31.1 mg HA/cm3 cortical density (p00.015) in HIV+ve wom-
en corresponds to a difference of 3.5 %.
Discussion
We investigated the influence of long-term, successfully
treated HIV infection on bone microstructure as evaluated
by HR-pQCT in premenopausal women compared with age-
and BMI-matched healthy controls. We observed structural
differences between HIV-infected women (with selective
structural bone alterations and lower lumbar spine BMD)
and HIV−ve premenopausal women.
Bone fragility is frequent in HIV-infected individuals. A
meta-analysis of cross-sectional studies conducted between
1996 and 2005 showed that 15 % of HIV-infected individuals
had osteoporosis and 52 % had osteopenia. Seropositive indi-
viduals were 6.4 times more likely to have low BMD and 3.7
times more likely to have osteoporosis than seronegative
controls [1]. Several analyses have identified risk factors pre-
disposing seropositive individuals to low BMD and increased
fracture risk. Some of these correspond to those observed in
the general population (vitaminD deficiency, low BMI, smok-
ing); vitamin D deficiency is highly prevalent among HIV+ve
individuals and has been associated with the use of certain
drug classes, namely non-nucleoside reverse transcriptase
inhibitors [24]; other factors are related to HIV infection itself,
such as HIV-RNA replication and low CD4 cell count. Use of
antiretroviral therapy has been implicated and, at least at
treatment initiation, HIV-infected patients experience a rapid
decrease in BMD [25]. Recent reports have suggested that the
overall risk of fracture in treated versus non-treated
individuals was reduced [26], but large cohort studies have
suggested a negative association of specific antiretroviral
drugs, such as tenofovir or boosted lopinavir [4]. To assess
fracture risk, DXA instruments are now widely available in
many countries, but this technique is not routinely recommen-
ded for premenopausal women, regardless of HIV status [27].
However, DXA scans have also limitations, and a significant
proportion of fracture risk cannot be explained by BMD alone.
Bone structural parameters appear to have an impact on bone
strength that is independent of BMD [11–13]. Indeed, differ-
ences in bone structural parameters in fractured subjects and
controls have been observed for the same level of aBMD in
HIV−ve women [11, 28, 29].
In our study, we observed a significant alteration in BMD
and bone microstructure among premenopausal HIV+ve
women, with a 14.1 % lower tibial trabecular bone density
compared to controls. After adjustment for the most com-
mon bone health variables, such as BMI, age, smoking
status, and vitamin D supplementation (yes/no), this effect
on trabecular variables was significant at the tibia site; being
HIV positive was the only explanatory variable for the
41.2 % decrease in distal tibia trabecular density in the
adjusted analysis. No such difference was found on the
distal radius trabecular density. Two factors may explain
this finding. First, the technique might be less prone to
movement artifacts during tibia image acquisition compared
to radius acquisition. Second, tibia is a weight-bearing bone
and is more prone to be associated with early structural
changes in trabecular bone. However, differences in cortical
density were observed at both sites with close to a signifi-
cant p value at the tibia site and a significant p value at
radius sites, but no significant differences in cortical
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Fig. 2 Percent difference (HIV+ve group versus HIV−ve controls) in distal radius and distal tibia microstructure (HR-pQCT) median pairs in
premenopausal women. *p0<0.05 obtained from univariate conditional logistic model which compared HIV+and the control group
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porosity were observed. All aspects of bone microstructure
were altered in HIV+ve successfully treated premenopausal
women. The evaluation of bone microstructure changes
using the same technique in hemodialysis patients has
shown relative changes to a similar extent in both radius
and tibia sites (29 % reduction in total and trabecular density
with a trabecular number reduced by 25 %) [30].
Our findings raise certain questions. Would an earlier
detection of these differences be useful if targeted to this
vulnerable population? Would these noninvasive methods
for assessing bone quality have a better discriminative pow-
er compared to standard aBMD determination by DXA?
Studies in men and women suffering from late-stage chronic
kidney disease do not tend to support this hypothesis as
BMD by DXA had the same ability to discriminate fracture
status as HR-pQCTwith no further improvement of fracture
discrimination when adding HR-pQCT data to BMD [31].
Although lumbar spine DXA values were lower (−6.9 %) in
HIV+ve women in our study, such a small difference would
probably not warrant a therapeutic intervention. HR-pQCT
alterations are not yet validated to precisely assess fracture
risk. Therefore, these two techniques should be considered
as complementary.
Our study has several limitations, such as a small sample
size, a cross-sectional design, and the lack of biochemical
data in controls, especially the absence of vitamin D plasma
levels in controls. However, both HIV+ve and control wom-
en had similar careful assessment performed by the same
investigator, thus adding confidence in the strength of our
data. In addition, our data cannot be extrapolated to women
with an uncontrolled HIV disease. We believe that prospec-
tive data would be welcome to confirm the results of our
study. Longer follow-up of these cohorts would be needed
to assess the exact fracture risk in women harboring early
structural changes, such as HIV+ve women. In the mean-
time, fracture risk can be decreased by a careful assessment
and correction of non-HIV-related factors, such as vitamin D
deficiency (57 % of our cohort had values lower than the
optimal 75 nmol/L threshold), alcohol and cigarette con-
sumption, or appropriate dietary intakes.
In conclusion, HIV+ve premenopausal women had
microstructural bone alterations and lower lumbar spine
BMD. These differences could all contribute to a higher
bone fragility in HIV+ve patients, and further research
is warranted in this population to determine if premen-
opausal screening might be beneficial to ensure early
preventive treatment and maintain quality of life in later
years.
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